129970-98-5

Basic information

• Product Name: (S)-Ethyl 2-((3S,5aS,9aS,10aS)-3-methyl-1,4-dioxodecahydropyrazino[1,2-a]indol-2(1H)-yl)pentanoate ,95%
• Synonyms: (S)-Ethyl 2-((3S,5aS,9aS,10aS)-3-methyl-1,4-dioxodecahydropyrazino[1,2-a]indol-2(1H)-yl)pentanoate ,95%;Perindopril Diketopiperazine;(αS,3S,5aS,9aS,10aS)-Decahydro-3-Methyl-1,4-dioxo-α-propylpyrazino[1,2-a]indole-2(1H)-acetic Acid Ethyl Ester;[3S-[2(R*),3α,5aβ,9aβ,10aβ]]-;Perindopril IMpurity – F (EP);Perindopril EP IMpurity F;Perindopril IMpurity F;Perindopril Related CoMpound F
• CAS NO: 129970-98-5
• Molecular Formula: C₁₉H₃₀N₂O₄
• Molecular Weight: 350.4525
• Product Categories: Amines;Chiral Reagents;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 129970-98-5.mol
• Article Data: 1

Chemical Properties

• Melting Point: 98-101°C
• Boiling Point: 526.1±50.0 °C(Predicted)
• Appearance: /
• Density: 1.17±0.1 g/cm3(Predicted)
• Storage Temp.: -20?C Freezer
• Solubility: Chloroform (Slightly), Ethyl Acetate (Slightly), Methanol (Sparingly)
• PKA: -1.15±0.40(Predicted)
• CAS DataBase Reference: (S)-Ethyl 2-((3S,5aS,9aS,10aS)-3-methyl-1,4-dioxodecahydropyrazino[1,2-a]indol-2(1H)-yl)pentanoate ,95%(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-Ethyl 2-((3S,5aS,9aS,10aS)-3-methyl-1,4-dioxodecahydropyrazino[1,2-a]indol-2(1H)-yl)pentanoate ,95%(129970-98-5)
• EPA Substance Registry System: (S)-Ethyl 2-((3S,5aS,9aS,10aS)-3-methyl-1,4-dioxodecahydropyrazino[1,2-a]indol-2(1H)-yl)pentanoate ,95%(129970-98-5)

Safety Data

• Hazardous Substances Data: 129970-98-5(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

Uses

Different sources of media describe the Uses of 129970-98-5 differently. You can refer to the following data:
1. Perindopril Diketopiperazine is an impurity of Perindopril (P287500).
2. Perindopril Diketopiperazine (Perindopril EP Impurity F) is an impurity of Perindopril (P287500).

Upstream product

• 107133-36-8 perindopril tert-butylamine 

Relevant articles and documents

STABLE FORMULATION OF AMORPHOUS PERINDOPRIL SALTS, A PROCESS FOR THEIR PREPARATION, ESPECIALLY INDUSTRIAL PREPARATION, AND THEIR USE IN THE THERAPY OF HYPERTENSION

There is disclosed a stable formulation of amorphous perindopril erbumine of the formula which is obtained in such a way that perindopril erbumine, which may also be prepared in situ from perindopril and tert-butylamine, or perindopril erbumine hydrate is dissolved in demineralized water or in a mixture of demineralized water and alcohol, to this solution a solution of sodium hydrogen carbonate is added for stabilization, inert ingredients for tabletting are wetted therewith, dried in vacuo by lyophilization or at normal pressure with a stream of warm air at not more than 40°C, hydrophobic additives to facilitate tabletting are added, it is homogenized and the granulate is tabletted. Disclosed is also a stable formulation of amorphous perindopril sodium salt obtained by modification of the drying procedure in the process of preparing the granulate. X-ray powder diffraction investigations show that perindopril erbumine is present in amorphous form and does not contain crystal α, β and γ forms.